Transactions
Jun. 18, 2002
SAN DIEGO DRUG COMPANY NETS SECOND ROUND FUNDS
Favrille Inc. netted $16.9 million in its recent second-round financing. The deal was announced June 11. Sanderling Ventures led the round. De Novo Ventures, Indofin NV, Lotus BioScience Investment Holdings Limited, Forward Ventures and Alloy Ventures were the other investors.
Sanderling Ventures led the round. De Novo Ventures, Indofin NV, Lotus BioScience Investment Holdings Limited, Forward Ventures and Alloy Ventures were the other investors.
San Diego's Favrille is a biotechnology company that produces drugs for patients with cancer and other auto-immune diseases. The company targets the genes in each patient to create a drug targeted to the patient's specific needs.
Palo Alto's Cooley Godward represented Favrille in the deal. San Diego partner Frederick Muto led the deal team, comprising associates David Berger and Danielle Bersofsky.
Paulette Taylor handled the deal in-house for Sanderling.
Stefanie Knapp
For reprint rights or to order a copy of your photo:
Email
Jeremy_Ellis@dailyjournal.com
for prices.
Direct dial: 213-229-5424
Send a letter to the editor:
Email: letters@dailyjournal.com